{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"15.08","upperLimit":"26.12","value":"19.91"},{"groupId":"OG001","lowerLimit":"6.47","upperLimit":"10.05","value":"8.11"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"94"},{"groupId":"OG001","value":"86"}],"units":"Participants"}],"title":"Participants with baseline PD-L1 expression ≥ 5%"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.93","upperLimit":"12.81","value":"9.86"},{"groupId":"OG001","lowerLimit":"8.54","upperLimit":"11.96","value":"10.28"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"137"},{"groupId":"OG001","value":"138"}],"units":"Participants"}],"title":"Participants with baseline PD-L1 expression < 5%"}],"denoms":[{"counts":[{"groupId":"OG000","value":"231"},{"groupId":"OG001","value":"224"}],"units":"Participants"}],"description":"Overall survival was defined as the time from randomization to the date of death. A participant who has not died will be censored at last known date alive. Overall Survival time was measured in months for all randomized participants grouped by their baseline PD-L1 expression level. PD-L1 expression in participants was defined as the percent of disease tumor cells demonstrating plasma membrane PD-L1 staining of any intensity using an immunohistochemistry (IHC) assay. Median computed using the Kaplan-Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Nivolumab 3 mg/kg solution administered intravenously every 2 weeks. Eligible participants transitioned to nivolumab 480 mg every 4 weeks. Participants treated until disease progression, discontinuation due to toxicity, withdrawal of consent or end of study.","id":"OG000","title":"Nivolumab"},{"description":"Docetaxel 75mg/m\\^2 solution administered intravenously every 3 weeks. Eligible participants transitioned to nivolumab 3 mg/kg every 2 weeks or 480 mg every 4 weeks. Participants treated until disease progression, discontinuation due to toxicity, withdrawal of consent or end of study.","id":"OG001","title":"Docetaxel"}],"paramType":"MEDIAN","populationDescription":"All randomized participants who had a tumor biopsy assessed for PD-L1 expression","reportingStatus":"POSTED","timeFrame":"From randomization to the date of death or last known date alive (up to approximately 110 months)","title":"Overall Survival (OS) by PD-L1 Expression at Baseline","type":"SECONDARY","unitOfMeasure":"Months"}